The Standard for Apple in the Enterprise Earnings Presentation: Fourth Quarter 2021 jamf Safe Harbor Unless otherwise specified, financial information and other data presented in this presented in this presented in the future. nber 31, 2021. The fin Armania and Charlos (collection) and charge provinsion in tradition de manak di 1984 tapes mainen ara 1981 kologan mintel se prosimpio norestria prosisten ministra prosis nema a senabled to real and unemaries int my casa activit sent manufacture manufaction with ...

Financial Performance - Full-Year 2024 private education loan originations reached $70 billion, a 10% increase compared to $64 billion in 2023[8] - Q4 2024 private education loan originations totaled $982 million, a 17% increase compared to $839 million in the year-ago quarter[11] - Full-Year 2024 GAAP diluted earnings per common share were $268[17] - The company repurchased 116 million shares in Full-Year 2024 for $250 million, at an average price of $2159 per share[13] Balance Sheet and Capital Allocation - Total assets grew by 31% in Full-Year 2024, inclusive of FFELP loan portfolio sale, while private education loan balance grew by 57%[9] - The total risk-based capital ratio was 126%, with a CET1 capital ratio of 113%[12] - $37 billion in private education loans were sold at attractive premiums in 2024, including $34 billion of principal and $274 million in capitalized interest[19] Credit Performance - The percentage of private education loans in repayment delinquent 30+ days as of December 31, 2024, was 37%, compared to 39% in 2023[25] - Private education loan net charge-offs for Full-Year 2024 were $332 million, representing 219% of average private education loans in repayment, compared with 244% in 2023[27] - Q4 2024 provision for credit losses was $108 million, with a total allowance of 583% as a percentage of the ending total loan balance plus unfunded commitments and total accrued interest receivable on private education loans[24] Funding and Liquidity - Deposit portfolio balances at the end of Q4 2024 were 18% lower than at the end of Q3 2024[20] - Uninsured deposits represented 3% of total deposits as of December 31, 2024[22]

Goldman Sachs Global Healthcare Conference June 10, 2025 Jay Duker, M.D. President and CEO ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the futur ...

Financial Performance & Ratios - UBSI achieved a net income of $373 million and diluted earnings per share of $2.75 in 2024[11] - The company's Return on Average Assets was 1.26%, Return on Average Equity was 7.61%, and Return on Average Tangible Equity was 12.43% in 2024[11] - Net Interest Margin (FTE) remained solid at 3.49%[11] - The efficiency ratio was 52.67%[11] Balance Sheet & Loan Portfolio - Total assets reached $30 billion, and pro forma total assets with Piedmont were $32 billion as of December 31, 2024[6] - Gross loans totaled $22 billion, and pro forma gross loans with Piedmont were $24 billion as of December 31, 2024[6] - Total deposits amounted to $24 billion, and pro forma total deposits with Piedmont were $26 billion as of December 31, 2024[6] - Non-Performing Assets (NPAs) increased to $73727000, representing 0.25% of total assets as of December 31, 2024[28] Piedmont Merger & Outlook - UBSI completed the merger with Piedmont Bancorp, Inc on January 10, 2025[8] - Net interest income (non-FTE) is expected to be in the range of $102 billion to $105 billion for 2025, including ~$20 million from Piedmont acquisition[54]

Investor Presentation February 2025 Most robust dataset in wet AMD and DME among all sustained delivery programs in development Two ongoing global Phase 3 non-inferiority pivotal trials in wet AMD Only sustained release TKI with active program in DME bolstered by highly positive Phase 2 clinical data ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform ...

Encompass Q3 Earnings 1 Forward-Looking Statements and Use of Non-GAAP Financial Measures and Key Performance Indicators Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding the Company's future results of operations and financial position, business strategy and plans ...

Financial Performance Highlights - GoHealth achieved record revenue of $877 million for FY 2020, representing a 63% increase year-over-year[7, 12] - Adjusted EBITDA for FY 2020 reached $271 million, a 59% increase compared to the previous year[7, 12] - The Adjusted EBITDA margin for FY 2020 was 31%[8, 12] - Q4 2020 revenue was $446 million, a 55% increase year-over-year[12] - Q4 2020 Adjusted EBITDA was $170 million, a 31% increase year-over-year, with a 38% margin[12, 27] Growth and Efficiency - Total submissions for FY 2020 were 730,000, a 71% increase year-over-year[6, 12] - Medicare-Internal segment revenue growth was 110% for FY 2020 and 75% for Q4 2020[12] - The company's commissions receivable balance grew by 112% to $810 million in 2020[29, 31] Outlook for 2021 - Projected revenue for FY 2021 is estimated to be between $1.15 billion and $1.3 billion, representing a growth of 31% to 48%[14] - Adjusted EBITDA for FY 2021 is projected to be between $345 million and $385 million, a growth of 27% to 42%[14] - The Adjusted EBITDA margin for FY 2021 is expected to be around 30%[14]

Exhibit 99.1 3rd Quarter 2024 Investment Thesis November 6, 2024 Slides 5 — 14 Executive Summary Forward-Looking Statements These materials contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"), notwithstanding that such statements are not specifically identified as such. In addition, certain statements may be contained in our future filings with the Securities and Exchange Commission ("SEC"), in press releases, and in oral and wr ...

Diversified Resilient Dynamic This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any of its affiliates nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or in connection with any other contract or commitment whatsoever. This presentation does not constitute a ...

Company Overview - Global Blue is a leader in tax-free shopping, operating at the intersection of travel and luxury retail, with a simple revenue model based on a percentage of tax-free spending[12] - The company estimates its enterprise value to be approximately €1.8 billion, calculated from an equity value of ~€1.2 billion plus net debt and other debt-like items of ~€0.6 billion[12, 13] - Global Blue's Tax Free Shopping (TFS) Sales in Store (SiS) completed amounted to €20 billion in FY23/24[15] - The company has a 70% market share in Tax Free Shopping[12, 26] Financial Performance - The company achieved over €200 million in annualized Adjusted EBITDA[11, 36] - Global Blue has historically demonstrated strong cash conversion, with over 80% cash conversion rate[12] - In FY23/24, Global Blue experienced a 36% year-over-year increase in Group Revenue and a 91% year-over-year increase in Adjusted EBITDA[34, 35] - Q1 FY24/25 results show a 25% year-over-year revenue growth and a 55% year-over-year Adjusted EBITDA growth, with an Adjusted EBITDA margin of 37%[37] Growth and Future Targets - The company is targeting long-term revenue growth of 8% to 12%[49, 50] - Global Blue is aiming for a long-term capital structure with net debt to LTM EBITDA ratio of less than 25x[51, 52] - The company is guiding for more than €200 million in EBITDA for the current financial year[49, 50]